Alopecia AreataNCT07226531
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
An observational study of Alopecia Areata, run by Pfizer at 1 site in United States.
Trial summary
Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders. In the United States (US), AA has an estimated point prevalence of 1.14% (Beningo et al., 2020). Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Alopecia Areata
- What is being tested?
- Ritlecitinib
- How many people
- 300 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Dec 2025to 6 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study will include patients with severe AA who initiated ritlecitinib (for treatment of severe AA) at least 6 months before the start of data collection. The study assumes that treatment with ritlecitinib was per label, as indicated for severe AA among patients at least 12 years of age. Data collection will be led by physicians (or their designated clinical assistants and staff, including nurse practitioners and physician assistants) recruited to the study who specialize in dermatology and are experienced in managing patients with AA.
Who may be able to join
- Confirmed diagnosis of severe AA (as determined by the treating physician)
- Initiated ritlecitinib for severe AA between 01 July 2023 and 28 February 2025
- At least 12 years of age at ritlecitinib initiation
- Has at least one additional follow-up visit/consultation after ritlecitinib initiation in which scalp hair loss was assessed
- Has a complete medical record regarding management or treatment of AA, covering the period initial AA diagnosis until their most recent follow-up/consultation
Who cannot join
- Ever diagnosed with other types of alopecia (i.e., e.g., chemotherapy-induced alopecia, androgenic alopecia [i.e., male pattern baldness], cicatricial alopecia [i.e., scarring alopecia], postpartum alopecia, or traction alopecia), other diseases (besides AA) that can cause hair loss, or other diseases that could interfere with assessment of hair loss/regrowth
- No documentation in the medical record of percent of scalp hair loss
- Participated in any clinical trial involving treatment with ritlecitinib, baricitinib, deuruxolitinib, delgocitinib, brepocitinib, or upadacitinib
Trial locations and contacts
1 site in 1 country.
About this study
Official title: RETROSPECTIVE COHORT STUDY TO ASSESS UTILIZATION AND EFFECTIVENESS OF RITLECITINIB IN A REAL-WORLD POPULATION WITH SEVERE ALOPECIA AREATA IN THE UNITED STATES
Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders. In the United States (US), AA has an estimated point prevalence of 1.14% (Beningo et al., 2020). The three most common subtypes of AA are defined by the affected area:
- Patchy alopecia (PA), as seen in 90% of clinical diagnoses: hair loss occurring in one or more patches (ranging from coin-sized to large patches and even full scalp involvement) on the scalp or other parts of the body;
- Alopecia totalis (AT): loss of all or nearly all scalp hair;
- Alopecia universalis (AU): loss of all or nearly all scalp, face, and body hair Traditionally, a range of medications, including corticosteroids, immunotherapy, and minoxidil, are used to treat AA. However, few of these mainstay therapies are supported by robust clinical evidence, limiting the development of widely accepted clinical practice guidelines (Asfour et al., 2023). As a result of suboptimal effectiveness of traditional therapies, patients with AA, particularly those with extensive hair loss, have a persistent unmet medical need. Furthermore, the potential effects of AA on other subgroups, including patients with skin of color, remain undefined. As these subgroups have been historically underrepresented in clinical trials, an additional unmet medical need and evidence gap exists for these patients.
Read more
Recent clinical studies have demonstrated efficacy of novel treatments for AA, including ritlecitinib, a JAK3/TEC family kinase inhibitor developed and marketed by Pfizer (King et al., 2023). Ritlecitinib was approved by the US Food and Drug Administration (FDA) in June 2023 for the treatment of severe AA in adults and adolescents aged 12 years or older. Extensive information from clinical trials exists on the safety and efficacy of ritlecitinib, which, along with JAK inhibitors such as baricitinib and deuruxolitinib that are FDA approved for severe alopecia areas in adults 18 and over, have presented needed new therapeutic options for these patients. However, little is known about the clinical effectiveness of ritlecitinib in real-world clinical practice.
The objective of the current study is to evaluate patient characteristics, treatment patterns and related clinical outcomes of patients who initiated ritlecitinib to treat severe AA.
- Conditions
- Alopecia Areata
- Being tested
- Ritlecitinib
- Medical subject headings
- Alopecia Areata
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RitlecitinibDrug
As provided in real-world practice
| Study group | Role | What they receive |
|---|---|---|
| Alopecia areata (AA) patients treated with ritlecitinib | Not described Receives: Drug: Ritlecitinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient demographics characteristics: race
Number of percentages of patients by race
Measured: Baseline
Patient demographics characteristics: sex, age at initial AA diagnosis, geographic location of patient's treating dermatologist, insurance type
Number of percentages of patients by sex
Measured: "Baseline" or "Day 1"
Patient demographics characteristics: age at initial AA diagnosis
Number of percentages of patients by age at initial AA diagnosis
Measured: "Baseline" or "Day 1"
Patient demographics characteristics: geographic location of patient's treating dermatologist
Number of percentages of patients by geographic location of patient's treating dermatologist
Measured: "Baseline" or "Day 1"
Patient demographics characteristics: insurance type
Number of percentages of patients by insurance type
Measured: "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: AA disease activity
Number of percentages of Patient clinical characteristics at initial AA diagnosis: AA disease activity
Measured: "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: SALT score
Number of percentages of Patient clinical characteristics at initial AA diagnosis: SALT score
Measured: "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: dermatology life quality index (DLQI) score
Number of percentages of Patient clinical characteristics at initial AA diagnosis: dermatology life quality index (DLQI) score
Measured: "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: eyebrow involvement
Number of percentages of Patient clinical characteristics at initial AA diagnosis: eyebrow involvement
Measured: "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: eyelash involvement
Number of percentages of Patient clinical characteristics at initial AA diagnosis: eyelash involvement
Measured: "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: beard involvement
Number of percentages of Patient clinical characteristics at initial AA diagnosis: beard involvement
Measured: "Baseline" or "Day 1"
Patient clinical characteristics at initial AA diagnosis: AA involvement at other body locations
Number of percentages of Patient clinical characteristics at initial AA diagnosis: AA involvement at other body locations
Measured: "Baseline" or "Day 1"
Patient treatment history: Additional treatment classes received during ritlecitinib treatment, additional treatment classes received after discontinuation of ritlecitinib, duration of each treatment class
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Characteristics of ritlecitinib treatment: Total duration of ritlecitinib exposure, reasons for ritlecitinib discontinuation (if ritlecitinib treatment stopped before last known clinic visit),
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: AA disease activity
AA disease activity reported as active hair loss or inactive hair loss
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: SALT score overall change from baseline
SALT score overall change from baseline (i.e., to last observed clinic visit), as well as change from baseline to predefined post-index time points (6-, 12-, 18-, and 24-months post-index, or other relevant timepoints based on actual distribution of data). Numeric and Categorical Data: no reduction from baseline, >0%-≤25% SALT reduction, >25%-≤50% SALT reduction, >50%-≤75% SALT reduction, >75% SALT reduction; Yes/No indicator for ≥30% SALT reduction; other categories/thresholds may also be applied.
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: SALT score
Numeric data, with categorical values of <50. 50-75, 75-100, and additional categories for ≥50 (to define severe AA) and 95-100 (to defined very severe AA); alternative categories may also be applied.
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving SALT ≤20 and ≤10
Landmark probabilities of achieving SALT≤20 and SALT≤10 at 6-, 12-, 18-, and 24-months post-index date, or other relevant timepoints based on actual distribution of data.
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving a sustained SALT response
Landmark probabilities of achieving a sustained SALT response at 6-, 12-, 18-, and 24-months post-index date, or other relevant timepoints based on actual distribution of data
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving ≥30% SALT score reduction from baseline at 6-, 12-, 18-, and 24-months post-index date
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: beard involvement
Categorical; none; minimal bear hair loss; moderate beard hair loss; severe beard hair loss; very severe or complete beard hair loss
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: eyebrow and eyelash involvement
Categorical data with values of 0 (no involvement), 1 (minimal gaps), 2 (significant gaps), or 3 (complete loss)
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: AA involvement at other body locations
Yes/no indicator for involvement at each of the following body sites: Extremities (arms, hands, legs, feet); Torso (chest, back, stomach); Pubic areas; Nasal hair; Nails
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: DLQI score
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: Patient report of feeling embarrassed or self-conscious because of AA
Yes; no; as documented by the physician at each clinic visit in the post-index date period
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: DLQI score overall change from baseline
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: patient report of AA affecting social or leisure activities
Yes; no; as documented by the physician at each clinic visit in the post-index date period
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: mental health comorbidities present at last known clinic visit
Yes; No; indicators for presence of specific psychiatric disorders examined in a prior systematic literature review by Lee et al. (2019)
Measured: "Day 1 through study completion, a minimum of 6-months follow-up"
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2025
- Study start22 Dec 2025
- Primary completion6 Mar 2026
- Study completion6 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alopecia AreataStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07226531
- Sponsor's protocol ID
- B7981121
- Status last verified
- Aug 2026
- First submitted
- 22 Sep 2025
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- RETROSPECTIVE COHORT STUDY TO ASSESS UTILIZATION AND EFFECTIVENESS OF RITLECITINIB IN A REAL-WORLD POPULATION WITH SEVERE ALOPECIA AREATA IN THE UNITED STATES
- ClinicalTrials.gov ID
- NCT07226531
- Acronym / sponsor ID
- B7981121
- Conditions
- Alopecia Areata
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 22 Dec 2025 (actual)
- Primary completion
- 6 Mar 2026 (actual)
- Study completion
- 6 Mar 2026 (actual)
- First posted
- 10 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders. In the United States (US), AA has an estimated point prevalence of 1.14% (Beningo et al., 2020). The three most common subtypes of AA are defined by the affected area:
- Patchy alopecia (PA), as seen in 90% of clinical diagnoses: hair loss occurring in one or more patches (ranging from coin-sized to large patches and even full scalp involvement) on the scalp or other parts of the body;
- Alopecia totalis (AT): loss of all or nearly all scalp hair;
- Alopecia universalis (AU): loss of all or nearly all scalp, face, and body hair Traditionally, a range of medications, including corticosteroids, immunotherapy, and minoxidil, are used to treat AA. However, few of these mainstay therapies are supported by robust clinical evidence, limiting the development of widely accepted clinical practice guidelines (Asfour et al., 2023). As a result of suboptimal effectiveness of traditional therapies, patients with AA, particularly those with extensive hair loss, have a persistent unmet medical need. Furthermore, the potential effects of AA on other subgroups, including patients with skin of color, remain undefined. As these subgroups have been historically underrepresented in clinical trials, an additional unmet medical need and evidence gap exists for these patients.
Recent clinical studies have demonstrated efficacy of novel treatments for AA, including ritlecitinib, a JAK3/TEC family kinase inhibitor developed and marketed by Pfizer (King et al., 2023). Ritlecitinib was approved by the US Food and Drug Administration (FDA) in June 2023 for the treatment of severe AA in adults and adolescents aged 12 years or older. Extensive information from clinical trials exists on the safety and efficacy of ritlecitinib, which, along with JAK inhibitors such as baricitinib and deuruxolitinib that are FDA approved for severe alopecia areas in adults 18 and over, have presented needed new therapeutic options for these patients. However, little is known about the clinical effectiveness of ritlecitinib in real-world clinical practice.
The objective of the current study is to evaluate patient characteristics, treatment patterns and related clinical outcomes of patients who initiated ritlecitinib to treat severe AA.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Alopecia areata (AA) patients treated with ritlecitinib | – | Drug: Ritlecitinib |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study will include patients with severe AA who initiated ritlecitinib (for treatment of severe AA) at least 6 months before the start of data collection. The study assumes that treatment with ritlecitinib was per label, as indicated for severe AA among patients at least 12 years of age. Data collection will be led by physicians (or their designated clinical assistants and staff, including nurse practitioners and physician assistants) recruited to the study who specialize in dermatology and are experienced in managing patients with AA.
Key inclusion criteria (5 listed)
- Confirmed diagnosis of severe AA (as determined by the treating physician)
- Initiated ritlecitinib for severe AA between 01 July 2023 and 28 February 2025
- At least 12 years of age at ritlecitinib initiation
- Has at least one additional follow-up visit/consultation after ritlecitinib initiation in which scalp hair loss was assessed
- Has a complete medical record regarding management or treatment of AA, covering the period initial AA diagnosis until their most recent follow-up/consultation
Key exclusion criteria (3 listed)
- Ever diagnosed with other types of alopecia (i.e., e.g., chemotherapy-induced alopecia, androgenic alopecia [i.e., male pattern baldness], cicatricial alopecia [i.e., scarring alopecia], postpartum alopecia, or traction alopecia), other diseases (besides AA) that can cause hair loss, or other diseases that could interfere with assessment of hair loss/regrowth
- No documentation in the medical record of percent of scalp hair loss
- Participated in any clinical trial involving treatment with ritlecitinib, baricitinib, deuruxolitinib, delgocitinib, brepocitinib, or upadacitinib
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RitlecitinibAs provided in real-world practice | Drug | Alopecia areata (AA) patients treated with ritlecitinib |
Primary outcome
Patient demographics characteristics: race
Time frame: Baseline
Number of percentages of patients by race
Patient demographics characteristics: sex, age at initial AA diagnosis, geographic location of patient's treating dermatologist, insurance type
Time frame: "Baseline" or "Day 1"
Number of percentages of patients by sex
Patient demographics characteristics: age at initial AA diagnosis
Time frame: "Baseline" or "Day 1"
Number of percentages of patients by age at initial AA diagnosis
Patient demographics characteristics: geographic location of patient's treating dermatologist
Time frame: "Baseline" or "Day 1"
Number of percentages of patients by geographic location of patient's treating dermatologist
Patient demographics characteristics: insurance type
Time frame: "Baseline" or "Day 1"
Number of percentages of patients by insurance type
Patient clinical characteristics at initial AA diagnosis: AA disease activity
Time frame: "Baseline" or "Day 1"
Number of percentages of Patient clinical characteristics at initial AA diagnosis: AA disease activity
Patient clinical characteristics at initial AA diagnosis: SALT score
Time frame: "Baseline" or "Day 1"
Number of percentages of Patient clinical characteristics at initial AA diagnosis: SALT score
Patient clinical characteristics at initial AA diagnosis: dermatology life quality index (DLQI) score
Time frame: "Baseline" or "Day 1"
Number of percentages of Patient clinical characteristics at initial AA diagnosis: dermatology life quality index (DLQI) score
Patient clinical characteristics at initial AA diagnosis: eyebrow involvement
Time frame: "Baseline" or "Day 1"
Number of percentages of Patient clinical characteristics at initial AA diagnosis: eyebrow involvement
Patient clinical characteristics at initial AA diagnosis: eyelash involvement
Time frame: "Baseline" or "Day 1"
Number of percentages of Patient clinical characteristics at initial AA diagnosis: eyelash involvement
Patient clinical characteristics at initial AA diagnosis: beard involvement
Time frame: "Baseline" or "Day 1"
Number of percentages of Patient clinical characteristics at initial AA diagnosis: beard involvement
Patient clinical characteristics at initial AA diagnosis: AA involvement at other body locations
Time frame: "Baseline" or "Day 1"
Number of percentages of Patient clinical characteristics at initial AA diagnosis: AA involvement at other body locations
Patient treatment history: Additional treatment classes received during ritlecitinib treatment, additional treatment classes received after discontinuation of ritlecitinib, duration of each treatment class
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Characteristics of ritlecitinib treatment: Total duration of ritlecitinib exposure, reasons for ritlecitinib discontinuation (if ritlecitinib treatment stopped before last known clinic visit),
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: AA disease activity
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
AA disease activity reported as active hair loss or inactive hair loss
Real-world clinical outcomes of ritlecitinib treatment: SALT score overall change from baseline
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
SALT score overall change from baseline (i.e., to last observed clinic visit), as well as change from baseline to predefined post-index time points (6-, 12-, 18-, and 24-months post-index, or other relevant timepoints based on actual distribution of data). Numeric and Categorical Data: no reduction from baseline, >0%-≤25% SALT reduction, >25%-≤50% SALT reduction, >50%-≤75% SALT reduction, >75% SALT reduction; Yes/No indicator for ≥30% SALT reduction; other categories/thresholds may also be applied.
Real-world clinical outcomes of ritlecitinib treatment: SALT score
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Numeric data, with categorical values of <50. 50-75, 75-100, and additional categories for ≥50 (to define severe AA) and 95-100 (to defined very severe AA); alternative categories may also be applied.
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving SALT ≤20 and ≤10
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Landmark probabilities of achieving SALT≤20 and SALT≤10 at 6-, 12-, 18-, and 24-months post-index date, or other relevant timepoints based on actual distribution of data.
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving a sustained SALT response
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Landmark probabilities of achieving a sustained SALT response at 6-, 12-, 18-, and 24-months post-index date, or other relevant timepoints based on actual distribution of data
Real-world clinical outcomes of ritlecitinib treatment: landmark probabilities of achieving ≥30% SALT score reduction from baseline at 6-, 12-, 18-, and 24-months post-index date
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: beard involvement
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Categorical; none; minimal bear hair loss; moderate beard hair loss; severe beard hair loss; very severe or complete beard hair loss
Real-world clinical outcomes of ritlecitinib treatment: eyebrow and eyelash involvement
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Categorical data with values of 0 (no involvement), 1 (minimal gaps), 2 (significant gaps), or 3 (complete loss)
Real-world clinical outcomes of ritlecitinib treatment: AA involvement at other body locations
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Yes/no indicator for involvement at each of the following body sites: Extremities (arms, hands, legs, feet); Torso (chest, back, stomach); Pubic areas; Nasal hair; Nails
Real-world clinical outcomes of ritlecitinib treatment: DLQI score
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: Patient report of feeling embarrassed or self-conscious because of AA
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Yes; no; as documented by the physician at each clinic visit in the post-index date period
Real-world clinical outcomes of ritlecitinib treatment: DLQI score overall change from baseline
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Real-world clinical outcomes of ritlecitinib treatment: patient report of AA affecting social or leisure activities
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Yes; no; as documented by the physician at each clinic visit in the post-index date period
Real-world clinical outcomes of ritlecitinib treatment: mental health comorbidities present at last known clinic visit
Time frame: "Day 1 through study completion, a minimum of 6-months follow-up"
Yes; No; indicators for presence of specific psychiatric disorders examined in a prior systematic literature review by Lee et al. (2019)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Alopecia Areata
RecruitingPhase 3
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Severe Alopecia Areata
Recruiting
A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia
Androgenetic Alopecia
Recruiting
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
Alopecia, Chemotherapy-induced Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alopecia Areata, run by Pfizer at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient demographics characteristics: race (time frame: Baseline). The study lists 28 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.